A Study for Patients With Non-Hodgkin's Lymphomas

You may be eligible if

• Have measurable lesions
• Have recovered from prior chemotherapies
• Have an estimated life expectancy of at least 12 weeks
• Hepatic: total bilirubin less than or equal to 1.5 XULN; ATL/AST less than or equal to 2.0 x ULN (less than 5x if liver metastases are present)
• Renal: serum creatinine less than or equal to 1.5XULN
• Adequate bone marrow reserve: platelets greater than or equal to 75 x 109 /Liter (L) Criteria:
• Have a second primary malignancy (except adequately treated nonmelanomatous skin cancer, or other cancer that is considered cured by surgical resection or radiation).
• Anti-lymphoma therapy within the past 3 weeks
• Unable to swallow tablets
• Unable to discontinue use of carbamazepine, phenobarbital and phenytoin at least 14 days prior to study enrollment